Recent Updates
Recently added Catalysts
LFCR Negative Sentiment Score: 30/100

LIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Lifecore Biomedical, Inc. Investors of Upcoming Deadline

Key Takeaway: Bernstein Liebhard LLP has issued a reminder to investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) regarding an upcoming deadline to file a lead plaintiff motion in a securities class action lawsuit. The lawsuit, filed in the District of Minnesota, alleges that the company violated the Securities Exchange Act of 1934 by maintaining deficient internal controls over financial reporting. As a result, several financial statements issued by Lifecore are said to be inaccurate and will need to be restated. Investors who acquired securities between October 7, 2020, and March 19, 2024, are encouraged to take action before the September 27, 2024, deadline.

Market Sentiment Analysis

CONCERNS & RISKS

  • Lifecore Biomedical is facing a securities class action lawsuit due to allegations of inadequate internal controls.
  • The lawsuit claims the company issued misleading financial statements that require restatement.
  • Investors who purchased shares during the specified period experienced financial losses.

Full Press Release Details

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR)?
Did you purchase your shares between October 7, 2020 and March 19, 2024, inclusive?
Did you lose money in your investment in Lifecore Biomedical, Inc.?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Lifecore Biomedical, Inc. (“Lifecore”) (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the District of Minnesota and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased or acquired Lifecore securities, and/or would like to discuss your legal rights and options please visit Lifecore Biomedical, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
According to the lawsuit, Lifecore maintained deficient internal controls over financial reporting, and issued several financial statements that were inaccurate and would need to be restated.
If you wish to serve as lead plaintiff for the Class, you must file papers by September 27, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the deadline to file a lead plaintiff motion?

The deadline to file a lead plaintiff motion is September 27, 2024.

What time period does the class action cover?

The class action covers shares purchased between October 7, 2020, and March 19, 2024.

Who can discuss their legal rights about Lifecore?

Investors who purchased Lifecore securities can discuss their legal rights.

Are there any fees for representation?

All representation is on a contingency fee basis; there are no fees for shareholders.

What allegations are made against Lifecore?

The lawsuit alleges Lifecore had deficient financial reporting controls and inaccurate statements.

Last updated: Sep 9, 2024